Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-5

  Corbo, Vincenzo ^a   Ritelli, Rossana ^a   Barbi, Stefano ^a   Funel, Niccola ^b   Campani, Daniela ^b   Bardelli, Alberto ^c   Scarpal, Aldo ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; B RAF KINASE; EPHRIN RECEPTOR A3; EPHRIN RECEPTOR B2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA SEQUENCE; GENE AMPLIFICATION; GENE INSERTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; ONCOGENE C KIT; PANCREAS ADENOCARCINOMA; PROTEIN DOMAIN; PROTEIN LOCALIZATION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TUMOR GENE; VATER PAPILLA CARCINOMA; ADULT; AGED; BILE DUCT TUMOR; ENZYMOLOGY; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PANCREAS CARCINOMA; PANCREAS TUMOR; TUMOR CELL LINE; VATER PAPILLA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMPULLA OF VATER; BASE SEQUENCE; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; COMMON BILE DUCT NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PANCREATIC NEOPLASMS; PROTEIN KINASES;

EID: 77958603990     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012653     Document Type: Article

References (51)

1. Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Natre 411: 355-365.
2. Nigg EA (2001) Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2: 21-32.
3. Hunter T (2000) Signaling-2000 and beyond. Cell 100: 113-127.
4. Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103: 211-225.
5. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298: 1912-1934.
6. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70.
7. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10: 789-799.
8. Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, et al. (2002) Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol Ther 93: 79-98.
9. Leary A, Johnston SR (2007) Small molecule signal transduction inhibitors for the treatment of solid tumors. Cancer Invest 25: 347-365.
10. Steeghs N, Nortier JW, Gelderblom H (2007) Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann Surg Oncol 14: 942-953.
11. Boultwood J (2001) Ataxia telangiectasia gene mutations in leukaemia and lymphoma. J Clin Pathol 54: 512-516.
12. Menoyo A, Alazzouzi H, Espin E, Armengol M, Yamamoto H, et al. (2001) Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability. Cancer Res 61: 7727-7730.
13. Merlos-Suarez A, Batlle E (2008) Eph-ephrin signalling in adult tissues and cancer. Curr Opin Cell Biol 20: 194-200.
14. Balakrishnan A, Bleeker FE, Lamba S, Rodolfo M, Daniotti M, et al. (2007) Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. Cancer Res 67: 3545-3550.
15. Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, et al. (2003) Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300: 949.
16. Davies H, Hunter C, Smith R, Stephens P, Greenman C, et al. (2005) Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 65: 7591-7595.
17. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, et al. (2004) A census of human cancer genes. Nat Rev Cancer 4: 177-183.
18. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, et al. (2007) Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158.
19. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274.
20. Stephens P, Edkins S, Davies H, Greenman C, Cox C, et al. (2005) A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 37: 590-592.
21. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, et al. (2007) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39: 347-351.
22. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, et al. (2007) The genomic landscapes of human breast and colorectal cancers. Science 318: 1108-1113.
23. Furuse J, Takada T, Miyazaki M, Miyakawa S, Tsukada K, et al. (2008) Guidelines for chemotherapy of biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg 15: 55-62.
24. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA (2006) Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 20: 1218-1249.
25. Sorio C, Bonora A, Orlandini S, Moore PS, Capelli P, et al. (2001) Successful xenografting of cryopreserved primary pancreatic cancers. Virchows Arch 438: 154-158.
26. Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, et al. (2001) Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch 439: 798-802.
27. Bader AG, Kang S, Vogt PK (2006) Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A 103: 1475-1479.
28. Ikenoue T, Kanai F, Hikiba Y, Obata T, Tanaka Y, et al. (2005) Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 65: 4562-4567.
29. Samuels Y, Diaz LA, Jr., Schmidt-Kittler O, Cummins JM, Delong L, et al. (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7: 561-573.
30. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
31. Jang JH, Shin KH, Park JG (2001) Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 61: 3541-3543.
32. Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, et al. (2007) Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 26: 7158-7162.
33. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
34. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806.
35. Immervoll H, Hoem D, Kugarajh K, Steine SJ, Molven A (2006) Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch 448: 788-796.
36. Ishimura N, Yamasawa K, Karim Rumi MA, Kadowaki Y, Ishihara S, et al. (2003) BRAF and K-ras gene mutations in human pancreatic cancers. Cancer Lett 199: 169-173.
37. Kullander K, Klein R (2002) Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 3: 475-486.
38. Alazzouzi H, Davalos V, Kokko A, Domingo E, Woerner SM, et al. (2005) Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. Cancer Res 65: 10170-10173.
39. Huusko P, Ponciano-Jackson D, Wolf M, Kiefer JA, Azorsa DO, et al. (2004) Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet 36: 979-983.
40. Pasquale EB (2005) Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol 6: 462-475.
41. Campbell TN, Robbins SM (2008) The Eph receptor/ephrin system: an emerging player in the invasion game. Curr Issues Mol Biol 10: 61-66.
42. Lee J, Jang KT, Ki CS, Lim T, Park YS, et al. (2007) Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 109: 1561-1569.
43. Tzeng CW, Frolov A, Frolova N, Jhala NC, Howard JH, et al. (2007) Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery 141: 464-469.
44. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, et al. (1998) Gainof-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577-580.
45. Zamo A, Bertolaso A, Franceschetti I, Weirich G, Capelli P, et al. (2007) Microfluidic deletion/insertion analysis for rapid screening of KIT and PDGFRA mutations in CD117-positive gastrointestinal stromal tumors: diagnostic applications and report of a new KIT mutation. J Mol Diagn 9: 151-157.
46. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480.
47. Bateman AC, Judd M, Radenkovic D, Johnson CD (2008) CD117/KIT expression in pancreatic adenocarcinoma. Pancreas 36: 76-79.
48. Yasuda A, Sawai H, Takahashi H, Ochi N, Matsuo Y, et al. (2006) The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells. Mol Cancer 5: 46.
49. Li J, Kleeff J, Guo J, Fischer L, Giese N, et al. (2003) Effects of STI571 (gleevec) on pancreatic cancer cell growth. Mol Cancer 2: 32.
50. Lee JW, Soung YH, Seo SH, Kim SY, Park CH, et al. (2006) Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res 12: 57-61.
51. Buttitta F, Barassi F, Fresu G, Felicioni L, Chella A, et al. (2006) Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer 119: 2586-2591.